Skip to main content

ABBV AbbVie Inc.

Healthcare

288.94 -5.95 -2.02% Close 11/2
Since 2024-12-02 +72.1%
Open
290.38
High
294.86
Low
286.14
Prev close
294.89
Volume
8.8M
Amplitude
2.96%
P/E
50.6
Revenue YoY (TTM)
+10.7%
52W 190.75 298.74

Is AbbVie Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Growth: Good, Momentum: Strong, Risk / liquidity: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but TTM P/E is Expensive.
TTM P/E 50.58 83th percentile Expensive
Price / book -87.8 N/A
Free-cash-flow yield (%) 3.78 61th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral Operating margin, TTM is Top, but ROE, TTM is Lagging.
ROE, TTM (%) -174.39 7th percentile Lagging
Operating margin, TTM (%) 35.53 86th percentile Top
FCF margin, TTM (%) 29.81 86th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Good Diluted EPS growth, TTM YoY is Top; Revenue growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 10.68 62th percentile Good
Diluted EPS growth, TTM YoY (%) 337.95 93th percentile Top
Momentum Strong 60-day return is Top; 240-day return is Good.
60-day return (%) 21.68 93th percentile Top
240-day return (%) 30.07 78th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Strong 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 1,433,078,704 99th percentile Top
60-day annualized volatility (%) 19.86 21th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

AbbVie Inc. (ABBV) today

3 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From AbbVie Inc. to every stock like it

AI finds several complementary traits of AbbVie Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like AbbVie Inc.

AbbVie Inc. (ABBV) peers and tracking

Watchlist

This page refreshes daily after the close. Add AbbVie Inc. to your watchlist to track signal changes on your next visit.

AbbVie Inc. (ABBV) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

26 historical occurrences (since 2017-03-15)

Average forward return after 52-week adjusted-price high

20-day: Win 65.4%, Sample 26, Median +1.24%, Excess +1.87%, Beat mkt rate 57.7%

60-day: Win 62.5%, Sample 24, Median +6.69%, Excess +3.22%, Beat mkt rate 62.5%

120-day: Win 81.8%, Sample 22, Median +9.42%, Excess +8.95%, Beat mkt rate 63.6%

120 days after: historical avg +14.84%

20-day +2.44%
60-day +5.26%
120-day +14.84%
20-day
60-day
120-day
Win
65.4%
62.5%
81.8%
Sample
26
24
22
Median
+1.24%
+6.69%
+9.42%
Excess
+1.87%
+3.22%
+8.95%
Beat mkt rate
57.7%
62.5%
63.6%

Over 22 occurrences, 120-day forward avg gained 14.84%, beat the market by 8.95 pts; win rate 81.8%.

Top-quintile 6-month momentum

Active · now 89.73%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
10 historical occurrences (since 2017-07-21)

Average forward return after Top-quintile 6-month momentum

20-day: Win 66.7%, Sample 9, Median +1.25%, Excess +1.91%, Beat mkt rate 44.4%

60-day: Win 77.8%, Sample 9, Median +15.13%, Excess +9.54%, Beat mkt rate 77.8%

120-day: Win 100%, Sample 9, Median +9.41%, Excess +12.97%, Beat mkt rate 66.7%

120 days after: historical avg +19.05%

20-day +3.94%
60-day +10.89%
120-day +19.05%
20-day
60-day
120-day
Win
66.7%
77.8%
100%
Sample
9
9
9
Median
+1.25%
+15.13%
+9.41%
Excess
+1.91%
+9.54%
+12.97%
Beat mkt rate
44.4%
77.8%
66.7%

Over 9 occurrences, 120-day forward avg gained 19.05%, beat the market by 12.97 pts; win rate 100%.

Filed revenue acceleration

Active · now 10.68%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

10 historical occurrences (since 2018-05-04)

Average forward return after Filed revenue acceleration

20-day: Win 60%, Sample 10, Median +0.6%, Excess +0.74%, Beat mkt rate 60%

60-day: Win 44.4%, Sample 9, Median -4.03%, Excess -3.43%, Beat mkt rate 22.2%

120-day: Win 50%, Sample 8, Median +3.33%, Excess -4.57%, Beat mkt rate 25%

120 days after: historical avg +2.73%

20-day +2.39%
60-day -0.69%
120-day +2.73%
20-day
60-day
120-day
Win
60%
44.4%
50%
Sample
10
9
8
Median
+0.6%
-4.03%
+3.33%
Excess
+0.74%
-3.43%
-4.57%
Beat mkt rate
60%
22.2%
25%

Over 8 occurrences, 120-day forward avg gained 2.73%, lagged the market by 4.57 pts; win rate 50%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 108+32.1% +30.6% 100% -6.6%
20-40 233+10.2% +8.3% 76.8% -6.6%
40-60 140+16.3% +17.2% 89.3% -2.8%
60-80 You are here188+25.6% +31.4% 92% +18.9%
80-100 775+24% +22.1% 100% +11.3%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 50.58, placing it in the 74.9 own-history percentile, inside the 60-80 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+8.1%
Win rate 87.2% Excess -6%
94d
+1.5%
Win rate 51.1% Excess -3.6%
221d
Now
+9.2%
Win rate 80.8% Excess +2.6%
642d
60-day momentum down
+14.4%
Win rate 96.3% Excess +1.4%
134d
+8.8%
Win rate 74.4% Excess 0%
86d
+19.2%
Win rate 97.2% Excess +11.5%
387d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 642 historical days, 120-day forward avg gained 9.2%, win rate 80.8%, beat the market by 2.6%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

7 times historically; 60-day forward avg +4.52%, win rate 80%, beating the market by +0.68 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.